Zealand Pharma is one step closer to delivering a fast-acting injectable for diabetes patients as their HypoPal rescue pen has cleared every primary and secondary endpoint in a Phase III trial on childhood hypoglycemia, confirming results already shown in adults and advancing the drug toward an early-2020 application for FDA approval. The injection, however, was not more effective than rival GlucaGen – and it did make a far higher percentage of teenagers throw up.
Shares of Zealand Pharma A/S are climbing in premarket trading after the company posted another late-stage success for dasiglucagon in treating severe hypoglycemia. This time, the treatment showed its strength in treating pediatric patients with diabetes.
Novo Nordisk recalls GlucaGen HypoKit in US after error at syringe supplier
PLAINSBORO, N.J., Sept. 8, 2016 /PRNewswire/ -- Novo Nordisk Inc. is recalling six batches of the GlucaGen® HypoKit® in the U.S. due to two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI). GlucaGen® HypoKit® is indicated for the treatment of severe hypoglycemia (low blood sugar) in patients with diabetes who are treated with insulin. A syringe with a detached needle cannot be used as prescribed.